Navigation Links
WuXi PharmaTech Announces CFO Benson Tsang to Leave Company; COO Edward Hu Named Acting CFO
Date:2/17/2009

SHANGHAI, Feb. 17 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX) announced today that Benson Tsang, Chief Financial Officer, is leaving the company for personal reasons at the end of February. Edward Hu, Chief Operating Officer, will serve as acting Chief Financial Officer until a replacement is found.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Mr. Tsang joined WuXi PharmaTech in 2006 as Chief Financial Officer. He made important contributions to the company's growth and development, including the successful initial public offering in August 2007, enhancement of the company's financial systems, and relationship building with investors and analysts in both China and the United States.

The board has formed a search committee to recruit a new Chief Financial Officer. Mr. Tsang has agreed to provide transition services and to assist in recruiting his successor. In the interim, Christine Lu-Wong, Vice President of Finance, will serve as the company's Principal Accounting Officer.

Mr. Hu joined WuXi PharmaTech in 2007 and has been Chief Operating Officer since January 2008. Before joining the company, he was Chief Operating Officer at Tanox, Inc., which was acquired by Genentech in 2007. He has more than a decade of experience in financial positions of increasing responsibility at Merck, Biogen Idec, and Tanox. He holds an M.B.A. and an M.S. in Biophysics and Biochemistry from Carnegie Mellon University.

"I want to thank Benson for his financial leadership during an important period in our company's history," said Dr. Ge Li, Chairman and CEO. "He leaves our company on a sound financial footing, with a solid balance sheet and strong long-term growth prospects. Ed Hu's appointment as interim Chief Financial Officer will ensure a smooth transition as we complete our search."

About WuXi AppTec and WuXi PharmaTech

WuXi AppTec is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi AppTec provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi AppTec's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi AppTec is an operating subsidiary of WuXi PharmaTech traded under NYSE symbol WX, formally WuXi PharmaTech (Cayman) Inc. For more information, please visit: http://www.wuxiapptec.com .

Cautionary Note Regarding Forward-Looking Statements

Statements in this release contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995, including those regarding the company's long-term growth prospects, strength of its balance sheet and its financial condition. It is also uncertain how long it will take to find a replacement CFO.

Forward-looking statements contained herein are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. Our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Factors that may adversely impair our growth prospects and financial condition include: uncertainty in the global economy may adversely impact our business and the trends for outsourced R&D and manufacturing; pharmaceutical and biotechnology companies may not change their business models as expected or in a manner favorable to us; we may fail to capitalize on the opportunities presented; we may not maintain our preferred provider status with our clients; and may be unable to expand our capabilities successfully to meet client needs. For additional information on these and other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on Page 10 of our 2007 Annual Report on Form 20-F available on the U.S. Securities and Exchange Commission's website at http://www.sec.gov .

    For more information, please contact:

     Ronald Aldridge (for investors)
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +1-215-218-5515
     Email: ir@wuxiapptec.com

     Sherry Shao (for the media)
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +86-21-5046-4002
     Email: pr@wuxiapptec.com

     Web:  http://www.wuxiapptec.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. WuXi PharmaTech Schedules 2007 Third Quarter Earnings Release on Monday, November 12, 2007
2. WuXi PharmaTech (NYSE: WX) CEO Honored with Ernst & Young Entrepreneur Of The Year China 2007 Award
3. WuXi PharmaTech Announces Third Quarter 2007 Results
4. WestChina-Frontier PharmaTech Awarded Full AAALAC Accreditation
5. WuXi PharmaTech (NYSE: WX) Mourns the Tragic Loss of Its Independent Director Shawn Wang
6. WuXi PharmaTech (NYSE: WX) Names Temporary Chairman of the Audit Committee
7. Princeton Professor David W. C. MacMillan Lectured WuXi PharmaTech Scientists
8. WuXi PharmaTech Announces Postponement of Proposed Follow-on Offering
9. Stanford Professor Barry M. Trost Visits WuXi PharmaTech and Gives Two Seminars
10. The First QPatch HT in China Placed in WuXi PharmaTech (NYSE: WX)
11. WuXi PharmaTech 2007 Annual Report Available Online
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Our bodies are bombarded ... to confront and deal with these stressors is to adopt a more healthful diet, ... for you. Risa Groux, a certified Holistic Nutritionist and the creator of the Newport ...
(Date:4/29/2016)... VA (PRWEB) , ... April 29, 2016 , ... ... with student loans more flexibility in repaying their loans, more information about their ... a time when total outstanding student loan debt, including federal and private loans, ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Spine Team Texas, ... is proud to announce one of their physicians has been invited to be a ... (Texas ACOFP) Family Practice Review conference on April 30, 2016. , Dr. R. ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Gluten-Free ... is pleased to announce the launch of the GFCP Scoop in ... more. The purpose of the GFCP Scoop site is to keep ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... Reltok ... devices and products for the head and neck/ear, nose and throat specialty, has added ... , The KOTLER NASAL AIRWAY™ is a newly patented safety device secured ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , Net Sales of $1.90 billion represent ... prior year period, and an increase of 1.2% on an ... for the first quarter were $0.52 reported, a decrease of ... increase of 29.9% over the prior year period , ... for 2016 Zimmer Biomet Holdings, Inc. (NYSE and ...
(Date:4/28/2016)... 28, 2016   Acsis , a leading provider ... IT market research and advisory firm IDC has named ... MarketScape: Worldwide Pharmaceutical Track and Trace Software 2016 Vendor ... an assessment of the capabilities and business strategies of ... market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/28/2016)... India , April 28, 2016 ... Pipeline Review, H1 2016" is a report that ... and helps strengthen R&D pipelines by identifying new ... products. Company Profiles discussed in this ... Industrie Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma ...
Breaking Medicine Technology: